It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).
Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).
Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).
Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).
Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).
Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).
Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).
Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).
It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).
It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).
It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).
It is very uncertain whether gestrinone changes side effects: hirsutism compared with danazol (very low certainty).
Gestrinone may leads to lower decreased breast size compared with danazol (low certainty).
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).